

Fangxin Hong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1460685/publications.pdf>

Version: 2024-02-01

97
papers

5,966
citations

117453

34
h-index

74018

75
g-index

100
all docs

100
docs citations

100
times ranked

9055
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Rapid Synthesis of Auxin via a New Tryptophan-Dependent Pathway Is Required for Shade Avoidance in Plants. <i>Cell</i> , 2008, 133, 164-176. | 13.5 | 928 |
| 2 | Different Plant Hormones Regulate Similar Processes through Largely Nonoverlapping Transcriptional Responses. <i>Cell</i> , 2006, 126, 467-475. | 13.5 | 859 |
| 3 | Network Discovery Pipeline Elucidates Conserved Time-of-Day-Specific cis-Regulatory Modules. <i>PLoS Genetics</i> , 2008, 4, e14. | 1.5 | 474 |
| 4 | MOLECULAR MECHANISMS OF STEROID HORMONE SIGNALING IN PLANTS. <i>Annual Review of Cell and Developmental Biology</i> , 2005, 21, 177-201. | 4.0 | 369 |
| 5 | Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Journal of Clinical Oncology</i> , 2013, 31, 684-691. | 0.8 | 256 |
| 6 | Signals from Chloroplasts Converge to Regulate Nuclear Gene Expression. <i>Science</i> , 2007, 316, 715-719. | 6.0 | 196 |
| 7 | Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 692-700. | 0.8 | 176 |
| 8 | Electronic Self-Report Assessment for Cancer and Self-Care Support: Results of a Multicenter Randomized Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 199-205. | 0.8 | 171 |
| 9 | Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1422-1428. | 0.8 | 150 |
| 10 | Subset of heat-shock transcription factors required for the early response of <i>Arabidopsis</i> to excess light. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 14474-14479. | 3.3 | 123 |
| 11 | Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. <i>Blood</i> , 2013, 121, 3547-3553. | 0.6 | 117 |
| 12 | RankProd 2.0: a refactored bioconductor package for detecting differentially expressed features in molecular profiling datasets. <i>Bioinformatics</i> , 2017, 33, 2774-2775. | 1.8 | 113 |
| 13 | Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia. <i>Clinical Cancer Research</i> , 2010, 16, 1033-1041. | 3.2 | 112 |
| 14 | The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. <i>British Journal of Haematology</i> , 2013, 161, 76-86. | 1.2 | 111 |
| 15 | Threats of Bots and Other Bad Actors to Data Quality Following Research Participant Recruitment Through Social Media: Cross-Sectional Questionnaire. <i>Journal of Medical Internet Research</i> , 2020, 22, e23021. | 2.1 | 109 |
| 16 | Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. <i>Journal of Clinical Oncology</i> , 2020, 38, 2407-2417. | 0.8 | 102 |
| 17 | The Personal Patient Profile-Prostate decision support for men with localized prostate cancer: A multi-center randomized trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1012-1021. | 0.8 | 95 |
| 18 | Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. <i>Cancer Discovery</i> , 2021, 11, 1952-1969. | 7.7 | 87 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90â€“Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. <i>Journal of Clinical Oncology</i> , 2012, 30, 3119-3126. | 0.8 | 86 |
| 20 | Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. <i>Lancet Haematology</i> , 2020, 7, e660-e670. | 2.2 | 86 |
| 21 | CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-mafâ€“mediated interactions with bone marrow stromal cells. <i>Blood</i> , 2009, 113, 4309-4318. | 0.6 | 75 |
| 22 | Decision preparation, satisfaction and regret in a multi-center sample of men with newly diagnosed localized prostate cancer. <i>Patient Education and Counseling</i> , 2012, 88, 262-267. | 1.0 | 66 |
| 23 | Metabolic sugar signal promotes Arabidopsis meristematic proliferation via G2. <i>Developmental Biology</i> , 2011, 351, 82-89. | 0.9 | 63 |
| 24 | Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. <i>Journal of Clinical Oncology</i> , 2021, 39, 1329-1338. | 0.8 | 60 |
| 25 | The electronic self report assessment and intervention for cancer: promoting patient verbal reporting of symptom and quality of life issues in a randomized controlled trial. <i>BMC Cancer</i> , 2014, 14, 513. | 1.1 | 56 |
| 26 | Evaluation of the International Prognostic Score (IPSâ€“7) and a Simpler Prognostic Score (IPSâ€“3) for advanced Hodgkin lymphoma in the modern era. <i>British Journal of Haematology</i> , 2015, 171, 530-538. | 1.2 | 54 |
| 27 | Self-reported adherence to oral cancer therapy: relationships with symptom distress, depression, and personal characteristics. <i>Patient Preference and Adherence</i> , 2015, 9, 1587. | 0.8 | 52 |
| 28 | Responseâ€“adapted therapy for aggressive nonâ€“Hodgkin's lymphomas based on early [18F] FDGâ€“PET scanning: ECOGâ€“ACRIN Cancer Research Group study (E3404). <i>British Journal of Haematology</i> , 2015, 170, 56-65. | 1.2 | 50 |
| 29 | Effect of Capiwasertib in Patients With an <i>AKT1 E17K</i> -Mutated Tumor. <i>JAMA Oncology</i> , 2021, 7, 271. | 3.4 | 49 |
| 30 | Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , 2018, 124, 136-144. | 2.0 | 47 |
| 31 | Bevacizumab and cyclophosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). <i>Leukemia and Lymphoma</i> , 2014, 55, 768-772. | 0.6 | 42 |
| 32 | Personalized risk prediction for eventâ€“free survival at 24 months in patients with diffuse large Bâ€“cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184. | 2.0 | 41 |
| 33 | Rituximab extended schedule or retreatment trial for low tumour burden nonâ€“follicular indolent Bâ€“cell nonâ€“Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. <i>British Journal of Haematology</i> , 2016, 173, 867-875. | 1.2 | 36 |
| 34 | Risk Factors for Depression in Patients Undergoing Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 946-950. | 2.0 | 35 |
| 35 | Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E). <i>Blood</i> , 2016, 128, 1106-1106. | 0.6 | 34 |
| 36 | Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1936-1942. | 0.8 | 33 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). <i>Cancer</i> , 2016, 122, 2996-3004. | 2.0 | 31 |
| 38 | Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. <i>Leukemia and Lymphoma</i> , 2012, 53, 718-720. | 0.6 | 26 |
| 39 | Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 821-826. | 3.2 | 26 |
| 40 | Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412). <i>Blood</i> , 2015, 126, 585-585. | 0.6 | 25 |
| 41 | Incremental value in outcome prediction with gene expression-based signatures in diffuse large B-cell lymphoma. <i>Blood</i> , 2013, 121, 156-158. | 0.6 | 20 |
| 42 | Patient-reported symptom distress, and most bothersome issues, before and during cancer treatment. <i>Patient Related Outcome Measures</i> , 2016, Volume 7, 127-135. | 0.7 | 20 |
| 43 | Psychosocial outcomes of an electronic self-report assessment and self-care intervention for patients with cancer: a randomized controlled trial. <i>Psycho-Oncology</i> , 2017, 26, 1866-1871. | 1.0 | 20 |
| 44 | Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. <i>British Journal of Haematology</i> , 2013, 160, 351-358. | 1.2 | 19 |
| 45 | A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages II) diffuse large B-cell non-Hodgkin lymphoma: ECOG 3402. <i>British Journal of Haematology</i> , 2015, 170, 679-686. | 1.2 | 19 |
| 46 | HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 675. | 2.2 | 18 |
| 47 | A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. <i>Clinical Cancer Research</i> , 2020, 26, 4468-4477. | 3.2 | 16 |
| 48 | Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 408-418. | 0.6 | 16 |
| 49 | Preliminary Pharmacokinetic (PK) Analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT). <i>Blood</i> , 2007, 110, 3420-3420. | 0.6 | 14 |
| 50 | Relationship between individual and family characteristics and psychosocial factors in persons with familial pancreatic cancer. <i>Psycho-Oncology</i> , 2018, 27, 1711-1718. | 1.0 | 13 |
| 51 | A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I). <i>Blood</i> , 2018, 132, 679-679. | 0.6 | 13 |
| 52 | Symptom-related emergency department visits and hospital admissions during ambulatory cancer treatment. <i>Journal of Community and Supportive Oncology</i> , 2015, 13, 188-194. | 0.1 | 13 |
| 53 | Exploring the impact of a decision support algorithm to improve clinicians' chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study. <i>BMC Cancer</i> , 2021, 21, 236. | 1.1 | 11 |
| 54 | Run-In Phase III Trial Design With Pharmacodynamics Predictive Biomarkers. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1628-1633. | 3.0 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. <i>Blood Cancer Journal</i> , 2018, 8, 27. | 2.8 | 10 |
| 56 | Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. <i>Journal of Clinical Oncology</i> , 2023, 41, 336-342. | 0.8 | 9 |
| 57 | Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CHOP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial. <i>Blood</i> , 2009, 114, 1671-1671. | 0.6 | 8 |
| 58 | Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496. <i>Blood</i> , 2010, 116, 416-416. | 0.6 | 8 |
| 59 | Evaluating Clinical Implementation Approaches for Prostate Cancer Decision Support. <i>Urology Practice</i> , 2019, 6, 93-99. | 0.2 | 7 |
| 60 | R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Long-Term Follow-up of Intergroup E4494/C9793. <i>Blood</i> , 2010, 116, 589-589. | 0.6 | 7 |
| 61 | Informing models of cancer genetics care in the era of multigene panel testing with patientâ€ed recommendations. <i>Journal of Genetic Counseling</i> , 2021, 30, 268-282. | 0.9 | 5 |
| 62 | Specific KIR and HLA Genotypes Affect Outcomes Of Single-Agent Anti-CD20 Immunotherapy Of Follicular Lymphoma. <i>Blood</i> , 2013, 122, 507-507. | 0.6 | 5 |
| 63 | Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial. <i>Blood</i> , 2016, 128, 2992-2992. | 0.6 | 5 |
| 64 | Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma: a study by the Eastern Co-operative Oncology Group (E1476) with >20 years follow-up. <i>Leukemia and Lymphoma</i> , 2009, 50, 1632-1641. | 0.6 | 4 |
| 65 | Patient–provider communication data: linking process and outcomes in oncology care. <i>Cancer Management and Research</i> , 2011, 3, 311. | 0.9 | 4 |
| 66 | Screening for Pain in the Ambulatory Cancer Setting: Is 0-10 Enough?. <i>Journal of Oncology Practice</i> , 2015, 11, 435-441. | 2.5 | 4 |
| 67 | Health behaviours and beliefs in individuals with familial pancreatic cancer. <i>Familial Cancer</i> , 2019, 18, 457-464. | 0.9 | 4 |
| 68 | Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Nonâ€Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 501-509. | 1.5 | 4 |
| 69 | Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. <i>Blood</i> , 2019, 134, 4092-4092. | 0.6 | 4 |
| 70 | Impact of Electronic Self-Assessment and Self-Care Technology on Adherence to Clinician Recommendations and Self-Management Activity for Cancer Treatmentâ€Related Symptoms: Secondary Analysis of a Randomized Controlled Trial. <i>JMIR Cancer</i> , 2019, 5, e11395. | 0.9 | 4 |
| 71 | Defining optimal initial therapy for primary CNS lymphoma. <i>Lancet Haematology</i> , 2016, 3, e206-e207. | 2.2 | 3 |
| 72 | The Jacki Jacket after mastectomy with reconstruction: a randomized pilot study. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 377-385. | 1.1 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. <i>Blood</i> , 2011, 118, 1603-1603. | 0.6 | 3 |
| 74 | Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. <i>Blood</i> , 2013, 122, 4277-4277. | 0.6 | 3 |
| 75 | Self-Reported Severity, Characteristics, and Functional Limitations of Chemotherapy-Induced Peripheral Neuropathy. <i>Pain Management Nursing</i> , 2021, , . | 0.4 | 3 |
| 76 | Decision support for men with prostate cancer: Concordance between treatment choice and tumor risk. <i>Cancer</i> , 2021, 127, 203-208. | 2.0 | 2 |
| 77 | A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).. <i>Blood</i> , 2012, 120, 2687-2687. | 0.6 | 2 |
| 78 | Validation of the Elderly IPI (E-IPI) for Patients with Diffuse Large B Cell Lymphoma Using An Independent Data Set From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). <i>Blood</i> , 2011, 118, 1568-1568. | 0.6 | 2 |
| 79 | Improved Risk Stratification With Addition Of Male Sex (S) To The Elderly International Prognostic Index (S-EIPI) For DLBCL Patients > 60 Years Treated With R-CHOP: An International Collaboration Of The US Intergroup, German High-Grade Non-Hodgkin Lymphoma Study Group and Groupe d'Etude De Lymphome d'Adultes. <i>Blood</i> , 2013, 122, 3045-3045. | 0.6 | 2 |
| 80 | The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imidazole Continuation (BIONIC) Study. <i>Blood</i> , 2018, 132, 1615-1615. | 0.6 | 1 |
| 81 | Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). <i>Blood</i> , 2018, 132, 623-623. | 0.6 | 1 |
| 82 | Chemokine Receptor Gene Polymorphisms and Severity of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation from Sibling Donors.. <i>Blood</i> , 2007, 110, 4989-4989. | 0.6 | 1 |
| 83 | A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma – a Correlative Study From the E2496 Intergroup Trial. <i>Blood</i> , 2011, 118, 430-430. | 0.6 | 1 |
| 84 | CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity Via C-Maf-Mediated Interactions with Bone Marrow Stromal Cells (BMSCs). <i>Blood</i> , 2008, 112, 840-840. | 0.6 | 1 |
| 85 | Gene Risk Scores Based on Expression of 6 Genes Quantitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study. <i>Blood</i> , 2011, 118, 87-87. | 0.6 | 1 |
| 86 | Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG) Tj ETQq0 0 0 rgBT.4 Overlook 10 Tf 50 | 0.6 | 1 |
| 87 | Transitioning from Heparin to Saline Locks for Central Venous Access Devices in Oncology: An Evidence-Based Practice Approach. <i>Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique</i> , 2022, 32, 286-293. | 0.1 | 1 |
| 88 | The effect of a lifestyle risk reduction intervention on lifestyle adherence and health-related quality of life in nonsmall cell lung cancer survivors: Feasibility study outcomes. <i>Psycho-Oncology</i> , 2019, 28, 920-923. | 1.0 | 0 |
| 89 | Reply to What is a good medical choice?. <i>Cancer</i> , 2021, 127, 1935-1936. | 2.0 | 0 |
| 90 | Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM).. <i>Blood</i> , 2008, 112, 1010-1010. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 91 | Gene Transcriptional Activity Analysis in the 6q Region in Waldenstrom Macroglobulinemia (WM) Using ChIP-on-Chip Technology. Blood, 2008, 112, 628-628. | 0.6 | 0 |
| 92 | Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.. Blood, 2009, 114, 2727-2727. | 0.6 | 0 |
| 93 | Incremental Value in Outcome Prediction with Molecular Signatures in Diffuse Large B-Cell Lymphoma,. Blood, 2011, 118, 3687-3687. | 0.6 | 0 |
| 94 | Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab. Blood, 2012, 120, 3705-3705. | 0.6 | 0 |
| 95 | Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499. Blood, 2015, 126, 2702-2702. | 0.6 | 0 |
| 96 | A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408. Blood, 2018, 132, 4157-4157. | 0.6 | 0 |
| 97 | Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma. Blood, 2021, 138, 815-815. | 0.6 | 0 |